#USA #Ultrasound #Charlottesville #RIVANNA #Accuro XV

RIVANNA's Accuro XV Ultrasound System Achieves FDA Clearance

In a significant milestone for medical technology, RIVANNA®, a company specializing in AI-driven clinical decision-support solutions, has announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Accuro XV musculoskeletal ultrasound imaging system. This approval allows qualified healthcare practitioners to utilize the system for advanced imaging of musculoskeletal conditions in hospital and clinic environments.

Revolutionary Features of the Accuro XV

The Accuro XV system is not just an ordinary ultrasound device; it incorporates cutting-edge artificial intelligence features aimed at improving diagnostic accuracy and workflow efficiency. Among its groundbreaking attributes is BoneEnhance®, a module designed for improved bone visualization through advanced image segmentation. Additionally, the CADe/x feature serves as an innovative computer-aided detection algorithm, which assists healthcare professionals in the rapid identification of fractures using volumetric ultrasound imaging. These capabilities are currently undergoing training and validation through a robust multi-site clinical study across eight leading academic medical centers throughout the United States.

Dr. Will Mauldin, Co-founder and CEO of RIVANNA, expressed that this FDA clearance represents a pivotal moment for the company. He stated, "This clearance illustrates the scalability of our core platform — the shared AI architecture, imaging hardware, and regulatory pathway — across distinct clinical applications. With no pointed solution in this space, we are set to redefine standards in the triage of extremity injuries.”

Advanced Technology for Enhanced Imaging

The Accuro XV system features a flexible three-dimensional volumetric ultrasound probe that enables automated acquisition of large field-of-view images, enhancing the examination process. By utilizing advanced motorized technology, the device can generate B-mode images covering a scan extent of 10 centimeters. A compliant polyurethane stand-off medium ensures proper acoustic coupling with various anatomical structures, making the imaging process smoother and more effective.

Equipped with an intuitive touchscreen interface and a portable battery pack, the Accuro XV system is designed for mobility in point-of-care settings. Moreover, it seamlessly integrates with DICOM-compatible workflows to ensure efficient image storage and retrieval.

Revolutionizing Emergency Medicine

According to Dr. Delphine Le Roux, Senior Director of Market Access and Strategic Partnerships at RIVANNA, the FDA clearance significantly accelerates the incorporation of artificial intelligence capabilities that will fully unlock the diagnostic potential of the Accuro XV system. She stated, “The combination of an automated acquisition platform with AI-based fracture detection can democratize access to high-quality musculoskeletal imaging and alleviate the load on imaging resources, especially in high-demand emergency environments.”

The recently published feasibility study on the Accuro XV reveals that non-physician operators can achieve diagnostic-quality extremity images after just one hour of training. Conducted at prestigious institutions like UVA Health and UT Southwestern Medical Center, the study involved 205 patients and reported that over 90% of scans from both operator groups met the standards for diagnostic interpretation.

Conclusion

RIVANNA’s Accuro XV musculoskeletal ultrasound imaging system stands as a testament to the merging of advanced technology and practical healthcare solutions. By supporting efficient emergency department workflows and enabling faster evaluations for low-severity extremity injuries, the Accuro XV is poised to enhance patient care while addressing the challenges posed by conventional imaging methods.

With federal support and adherence to rigorous standards, RIVANNA continues its mission to revolutionize musculoskeletal injury care while aligning with broader goals of emergency preparedness. As RIVANNA advances its technology, the future of musculoskeletal imaging looks promising and transformative.